Comparison · NCT00353496-sae
Lanreotide (Autogel Formulation) vs Placebo: serious adverse events
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
2 sourcestrial-comparisons-2026-03-23-0.1.0
Cite this record
ConductScience Library. Lanreotide (Autogel Formulation) vs Placebo: serious adverse events. Trial comparisons, record NCT00353496-sae. Release trial-comparisons-2026-03-23-0.1.0, 23 Mar 2026. https://conductscience.org/library/comparisons/NCT00353496-sae
On this page
Measures6
Calculated by ConductScience from the counts the trial posted to ClinicalTrials.gov.
| Measure | Value | 95% interval, lower | 95% interval, upper | Method | Note |
|---|---|---|---|---|---|
| Risk in group 1 | 0.248 | 0.174 | 0.34 | wilson | |
| Risk in group 2 | 0.311 | 0.229 | 0.405 | wilson | |
| Risk difference, group 1 minus group 2 | -0.0632 | -0.183 | 0.0598 | newcombe hybrid score | |
| Risk ratio, group 1 over group 2 | 0.797 | 0.51 | 1.24 | log | |
| Odds ratio, group 1 over group 2 | 0.73 | 0.395 | 1.35 | log | |
| Number needed to treat, for one fewer participant with a serious adverse event on Lanreotide (Autogel Formulation) than on Placebo | 15.8 | from the risk difference interval | the interval includes no difference |
Source ClinicalTrials.gov
Groups2
Group 2 names the comparator: placebo.
| Group | Title | Description | With the outcome | Analysed | ClinicalTrials.gov code |
|---|---|---|---|---|---|
| Group 1 | Lanreotide (Autogel Formulation) | 120mg administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks. | 25 | 101 | EG000 |
| Group 2 | Placebo | Saline solution 0.9% administered via deep subcutaneous injection every 28 days for a maximum period of 96 weeks. | 32 | 103 | EG001 |
Source ClinicalTrials.gov
Harm
- What it counts
- Total, serious adverse events
- Time frame
- Total exposure to treatment was 138.0 subject years for lanreotide vs 123.6 subject years for placebo.
Source ClinicalTrials.gov
Trial
- Title
- Study of Lanreotide Autogel in Non-functioning Entero-pancreatic Endocrine Tumours
- NCT number
- NCT00353496
- Phases
- PHASE3
- Conditions
- Endocrine Tumors
- Interventions
- lanreotide (Autogel formulation), Placebo
- Lead sponsor
- Ipsen
- Results first posted
- 2015-02-18
- Results on ClinicalTrials.gov
- https://clinicaltrials.gov/study/NCT00353496?tab=results
Source ClinicalTrials.gov
Source
- Release
- trial-comparisons-2026-03-23-0.1.0
- Release manifest SHA-256
- f66225897fbf258b57ea10bdacfd0347d3cdfda93f7f5685234b7e06ea36fa57
- AACT copy
- 2026-03-23
- Tables read
- outcome_counts.parquet, outcome_measurements.parquet, outcomes.parquet, reported_event_totals.parquet, reported_events.parquet, result_groups.parquet, studies.parquet, ctgov_trial.parquet
Source ClinicalTrials.gov
Sources 2
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
For software
Read this comparison from software.
The record is JSON. No key.
GET https://conductscience.org/api/comparisons/v1/NCT00353496-sae